시장보고서
상품코드
1303137

암 마이크로바이옴 시퀀싱 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측(2017-2027년)

Cancer Microbiome Sequencing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Component, By Technology, By Application, By End User, By company and By Region

발행일: | 리서치사: TechSci Research | 페이지 정보: 영문 116 Pages | 배송안내 : 2-3일 (영업일 기준)


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 암 마이크로바이옴 시퀀싱 시장은 2023-2027년 예측 기간 동안 괄목할 만한 성장을 보일 것으로 예상됩니다.

암 발생 건수의 증가와 암 분야에서 마이크로바이옴의 잠재력에 대한 관심이 높아지는 등 주요 요인이 시장 성장에 박차를 가하고 있습니다. 마이크로바이옴은 타액, 피부층, 인체의 구강 점막, 소화관 등의 환경에서 증식하거나 존재하는 미생물 군집입니다. 마이크로바이옴 시퀀싱은 인간의 미생물을 더 깊이 이해하기 위해 인체 내 또는 체외에 존재하는 미생물 군집을 연구하고 분석하는 데 사용되는 귀중한 도구입니다. 마이크로바이옴 연구의 주요 목적은 인간의 건강과 질병에서 미생물의 역할과 기능을 이해하는 것입니다. 시장 성장을 뒷받침하는 다른 요인으로는 시퀀싱 비용의 감소, 연구개발 활동의 활성화, 전 세계 암 환자 수의 급격한 증가, 임상시험의 증가, 의사들을 지원하기 위한 마이크로바이옴 기반의 새로운 진단 도구의 개발 증가, 생명공학 기업들의 투자 증가, 질병 진단 및 조기 발견을 위한 마이크로바이옴 시퀀싱 서비스에 대한 수요 증가, 전 세계 인구 증가, 마이크로바이옴 시퀀싱 기술 사용에 대한 인식 증가, 의료비 지출 증가, 인간 건강과 질병에서 마이크로바이옴의 역할에 대한 이해에 대한 연구 연구자들의 관심 증가, 신흥 하위 시장에 대한 무한한 잠재력 등이 있습니다.

암 발병률 증가가 시장 성장을 뒷받침합니다.

폐암, 자궁경부암, 유방암, 피부암, 인두암 등 암 발병률의 증가는 시장 성장을 견인하고 있습니다. WHO에 따르면 2020년 암은 전 세계적으로 약 1,000만 명, 사망자 6명 중 1명이 암으로 사망하는 주요 사망 원인으로 보고되고 있습니다. 가장 흔한 암은 폐암, 대장암, 전립선암, 유방암입니다. 음주, 흡연, 불건강한 식습관, 앉아서 생활하는 생활습관 등으로 인해 암에 걸리는 경우가 급증하고 있습니다. 이에 따라 암 마이크로바이옴 시퀀싱에 대한 수요가 증가하고 있으며, 이는 시장 성장을 견인하고 있습니다. WHO에 따르면 많은 암은 조기에 발견하면 효과적으로 치료할 수 있습니다.

마이크로바이옴의 잠재력에 대한 연구자들의 관심이 높아지고, 생명공학 기업들의 지원도 증가하고 있습니다.

다양한 암 진단 및 예방에 대한 마이크로바이옴의 잠재력에 대한 관심이 높아지면서 시장 성장을 견인하고 있습니다. 다양한 연구자들이 암 분야에서 마이크로바이옴의 잠재력을 조사하고 연구하고 있습니다. 연구자들은 마이크로바이옴이 암의 진행과 발현에 미치는 영향에 대한 인사이트를 얻기 위해 생명공학 기업의 지원을 받고 있습니다. 또한, 암 마이크로바이옴 시퀀싱 서비스 및 제품 개발은 연구 커뮤니티가 마이크로바이옴과 관련된 새로운 암 바이오마커를 발견할 수 있는 효과적인 전략을 수립하는 데 도움을 주고 있습니다.

사용 가능한 커스터마이징

TechSci Research는 주어진 시장 데이터를 사용하여 기업의 특정 요구에 따라 맞춤형으로 제공합니다. 보고서에는 다음과 같은 커스터마이징이 가능합니다.

회사 소개

  • 추가 시장 진입 기업(최대 5개사)에 대한 심층 분석 및 프로파일링

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 COVID-19가 세계의 암 마이크로바이옴 시퀀싱 시장에 미치는 영향

제5장 고객의 소리

제6장 암 마이크로바이옴 시퀀싱 세계 시장 전망

  • 시장 규모 및 예측
    • 금액별
  • 시장 점유율과 예측
    • 컴포넌트별
    • 기술별
    • 용도별
    • 최종사용자별
    • 기업별
    • 지역별
  • 시장 맵

제7장 북미의 암 마이크로바이옴 시퀀싱 시장 전망

  • 시장 규모 및 예측
    • 금액별
  • 시장 점유율과 예측
    • 컴포넌트별
    • 기술별
    • 용도별
    • 최종사용자별
    • 국가별
  • 북미 국가별 분석
    • 미국
    • 캐나다
    • 멕시코

제8장 유럽의 암 마이크로바이옴 시퀀싱 시장 전망

  • 시장 규모 및 예측
    • 금액별
  • 시장 점유율과 예측
    • 컴포넌트별
    • 기술별
    • 용도별
    • 최종사용자별
    • 국가별
  • 유럽 국가별 분석
    • 프랑스
    • 독일
    • 영국
    • 이탈리아
    • 스페인

제9장 아시아태평양의 암 마이크로바이옴 시퀀싱 시장 전망

  • 시장 규모 및 예측
    • 금액별
  • 시장 점유율과 예측
    • 컴포넌트별
    • 기술별
    • 용도별
    • 최종사용자별
    • 국가별
  • 아시아태평양 국가별 분석
    • 중국
    • 인도
    • 일본
    • 한국
    • 호주

제10장 남미의 암 마이크로바이옴 시퀀싱 시장 전망

  • 시장 규모 및 예측
    • 금액 기준
  • 시장 점유율과 예측
    • 컴포넌트별
    • 기술별
    • 용도별
    • 최종사용자별
    • 국가별
  • 남미 : 국가별 분석
    • 브라질
    • 아르헨티나
    • 콜롬비아

제11장 중동 및 아프리카의 암 마이크로바이옴 시퀀싱 시장 전망

  • 시장 규모 및 예측
    • 금액 기준
  • 시장 점유율과 예측
    • 컴포넌트별
    • 기술별
    • 용도별
    • 최종사용자별
    • 국가별
  • MEA : 국가별 분석
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트
    • 터키
    • 이집트

제12장 시장 역학

  • 성장 촉진요인
  • 과제

제13장 시장 동향과 발전

제14장 경쟁 상황

  • Illumina, Inc.
  • Eurofins Scientific SE
  • QIAGEN NV
  • Thermo Fischer Scientific, Inc.
  • Oxford Nanopore Technologies plc.
  • OraSure Technologies, Inc.
  • Pacific Biosciences of California, Inc.
  • Psomagen, Inc
  • Prescient Medicine Holdings, Inc.
  • Micronoma Inc.

제15장 전략적 제안

ksm 23.08.21

The global cancer microbiome sequencing market is anticipated to observe impressive growth during the forecast period 2023-2027. The major factors, including growing occurrences of cancer and increasing emphasis on the microbiome's potential in the field of cancer, are fueling the growth of the market. Microbiomes are the community of microorganisms that grow or exist in an environment, such as saliva, skin layers, oral mucosa of the human body, and the gastrointestinal tract. Microbiome sequencing is a valuable tool that is used to study and analyze the microbes groups located in or out of the human body to have a better understanding of human microbes. The main aim of a microbiome research study is to understand the role and function of microbes in human health and disease. The other factors supporting the market's growth are decreasing cost of sequencing, the rise in R&D activities, the exponential rise in the number of cancer cases worldwide, the increasing number of clinical trials, the rise in the development of novel diagnostic tools based on the microbiome for supporting physicians, increasing investments by biotechnology companies, rise in demand for microbiome sequencing services for diagnosis and early detection of the diseases, rise in world population, growing awareness of the use of microbiome sequencing technology, rise in the healthcare expenditure, rising interest of researchers in understanding the role of the microbiome in human health and disease, and immense potential for emerging submarkets.

The rising Prevalence of Cancer supports Market Growth.

Growing incidences of cancer, such as lung, cervical, breast, skin, throat, and others, are augmenting the growth of the market. According to WHO, in 2020, cancer is a major cause of death across the world, reporting approximately 10 million deaths, or about one in six deaths. The most common cancers are lung, colon and rectum, prostate cancers, and breast. There is a surge in the number of cases suffering from cancer caused due to consumption of alcohol, tobacco use, unhealthy eating choices, and sedentary lifestyle. Therefore, the need for cancer microbiome sequencing is rising, which in turn, bolsters the growth of the market. As per WHO, many cancers can be treated effectively if detected in an early stage.

Increasing Emphasis by Researchers on the Microbiome's Potential and Rising Support from Biotechnology Companies.

The rising focus on the microbiome's potential to diagnose and prevent various cancers is fueling the growth of the market. Various researchers are studying and researching the microbiome's potential in the field of cancers. Researchers are being supported by biotech companies to unravel insights pertaining to the microbiome's influence on cancer progression and manifestation. Furthermore, the development of cancer microbiome sequencing services and products has aided the research community in creating effective strategies for discovering novel cancer biomarkers allied with the microbiome, which could be used for the development of cancer microbiome sequencing products for clinical use.

Market Segmentation

The global cancer microbiome sequencing market is segmented into components, technology, application, end-user, and company. Based on components, the market is divided into kits & assays, software, and services. Based on technology, the market is divided into next-generation sequencing and polymerase chain reaction. Based on application, the market is divided into translational research and clinical diagnostics. Based on end-user, the market is divided into biotechnology & pharmaceutical companies, academic & research institutions, hospitals & clinics, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to rising incidences of cancer and a rise in R&D activities in the country.

Market Players

Illumina, Inc., Eurofins Scientific SE, QIAGEN NV, Thermo Fischer Scientific, Inc., Oxford Nanopore Technologies plc., OraSure Technologies, Inc., Pacific Biosciences of California, Inc., Psomagen, Inc, Prescient Medicine Holdings, Inc., and Micronoma Inc. are some of the leading companies operating in the market.

Report Scope

In this report, global cancer microbiome sequencing market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Cancer Microbiome Sequencing Market, By component:

  • Kits & Assays
  • software
  • Services

Cancer Microbiome Sequencing Market, By technology:

  • Next-Generation Sequencing
  • Polymerase Chain Reaction

Cancer Microbiome Sequencing Market, By application:

  • Translational Research
  • Clinical Diagnostics

Cancer Microbiome Sequencing Market, By End User:

  • Biotechnology & Pharmaceutical Companies,
  • Academic & Research Institutions
  • Hospitals & Clinics
  • Others

Cancer Microbiome Sequencing Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Europe & CIS
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Turkey
    • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Cancer Microbiome Sequencing Market

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Cancer Microbiome Sequencing Market

5. Voice of Customer

6. Global Cancer Microbiome Sequencing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Component (Kits & Assays, Software, Services)
    • 6.2.2. By Technology (Next Generation Sequencing v/s Polymerase Chain Reaction)
    • 6.2.3. By Application (Translational Research v/s Clinical Diagnostics)
    • 6.2.4. By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Hospitals & Clinics, Others)
    • 6.2.5. By Company (2021)
    • 6.2.6. By Region
  • 6.3. Market Map

7. North America Cancer Microbiome Sequencing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Component
    • 7.2.2. By Technology
    • 7.2.3. By Application
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Cancer Microbiome Sequencing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Component
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By End User
    • 7.3.2. Canada Cancer Microbiome Sequencing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Component
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By End User
    • 7.3.3. Mexico Cancer Microbiome Sequencing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Component
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By End User

8. Europe Cancer Microbiome Sequencing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Component
    • 8.2.2. By Technology
    • 8.2.3. By Application
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Cancer Microbiome Sequencing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Component
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By End User
    • 8.3.2. Germany Cancer Microbiome Sequencing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Component
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By End User
    • 8.3.3. United Kingdom Cancer Microbiome Sequencing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Component
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By End User
    • 8.3.4. Italy Cancer Microbiome Sequencing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Component
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By End User
    • 8.3.5. Spain Cancer Microbiome Sequencing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Component
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By End User

9. Asia-Pacific Cancer Microbiome Sequencing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Component
    • 9.2.2. By Technology
    • 9.2.3. By Application
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Cancer Microbiome Sequencing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Component
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By End User
    • 9.3.2. India Cancer Microbiome Sequencing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Component
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By End User
    • 9.3.3. Japan Cancer Microbiome Sequencing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Component
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By End User
    • 9.3.4. South Korea Cancer Microbiome Sequencing Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Component
        • 9.3.4.2.2. By Technology
        • 9.3.4.2.3. By Application
        • 9.3.4.2.4. By End User
    • 9.3.5. Australia Cancer Microbiome Sequencing Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Component
        • 9.3.5.2.2. By Technology
        • 9.3.5.2.3. By Application
        • 9.3.5.2.4. By End User

10. South America Cancer Microbiome Sequencing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Component
    • 10.2.2. By Technology
    • 10.2.3. By Application
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Cancer Microbiome Sequencing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Component
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By End User
    • 10.3.2. Argentina Cancer Microbiome Sequencing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Component
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By End User
    • 10.3.3. Colombia Cancer Microbiome Sequencing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Component
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By End User

11. Middle East and Africa Cancer Microbiome Sequencing Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Component
    • 11.2.2. By Technology
    • 11.2.3. By Application
    • 11.2.4. By End User
    • 11.2.5. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Cancer Microbiome Sequencing Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Component
        • 11.3.1.2.2. By Technology
        • 11.3.1.2.3. By Application
        • 11.3.1.2.4. By End User
    • 11.3.2. Saudi Arabia Cancer Microbiome Sequencing Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Component
        • 11.3.2.2.2. By Technology
        • 11.3.2.2.3. By Application
        • 11.3.2.2.4. By End User
    • 11.3.3. UAE Cancer Microbiome Sequencing Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Component
        • 11.3.3.2.2. By Technology
        • 11.3.3.2.3. By Application
        • 11.3.3.2.4. By End User
    • 11.3.4. Turkey Cancer Microbiome Sequencing Market Outlook
      • 11.3.4.1. Market Size & Forecast
        • 11.3.4.1.1. By Value
      • 11.3.4.2. Market Share & Forecast
        • 11.3.4.2.1. By Component
        • 11.3.4.2.2. By Technology
        • 11.3.4.2.3. By Application
        • 11.3.4.2.4. By End User
    • 11.3.5. Egypt Cancer Microbiome Sequencing Market Outlook
      • 11.3.5.1. Market Size & Forecast
        • 11.3.5.1.1. By Value
      • 11.3.5.2. Market Share & Forecast
        • 11.3.5.2.1. By Component
        • 11.3.5.2.2. By Technology
        • 11.3.5.2.3. By Application
        • 11.3.5.2.4. By End User

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Illumina, Inc.
  • 14.2. Eurofins Scientific SE
  • 14.3. QIAGEN NV
  • 14.4. Thermo Fischer Scientific, Inc.
  • 14.5. Oxford Nanopore Technologies plc.
  • 14.6. OraSure Technologies, Inc.
  • 14.7. Pacific Biosciences of California, Inc.
  • 14.8. Psomagen, Inc
  • 14.9. Prescient Medicine Holdings, Inc.
  • 14.10. Micronoma Inc.

15. Strategic Recommendations

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제